secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001193125-24-097764
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics: all 8 heme patients relapse-free >10 months; solid tumor 60% qualify
--------------------------------------------------------------------------------

- All 8 TSC-100/101 treated patients remain MRD-negative and relapse-free (median follow-up >10 months); no dose-limiting toxicities.
- Control arm (transplant alone) had 2 relapses at ~6 months and 1 death; only 1 of 8 achieved complete donor chimerism.
- Solid tumor: >40 patients screened; ~60% qualify for at least one TCR-T, ~30% eligible for multiplex (T-Plex) therapy.
- First 3 solid tumor patients expected to be dosed early May 2024; initial data from singleplex and multiplex cohorts in H2 2024.
- Heme: expansion cohorts at Phase 2 dose planned Q3 2024; Phase 1 enrollment completion and 1-year data in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524097764/0001193125-24-097764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524097764/d820546d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-097764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer